KDR and adrenal cortex carcinoma: Although there are no FDA-approved systemic therapy options available for ACC, most clinicians use multi-kinase inhibitors targeting vascular endothelial growth factor receptor (VEGFR) pathways, as agents including lenvatinib and axitinib have demonstrated modest clinical benefit in these patients.